Nano drug delivery systems improve metastatic breast cancer therapy

Zhu, Rui; Lang, Tianqun; Yin, Qi; Li, Yaping

doi:10.1515/mr-2021-0011

Cited by 9 publications

(5 citation statements)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 17 ] On the other hand, recent investigations define the adverse effects of nanoparticle‐based drug deliveries, which enhance the permeability of the tumor‐associated blood supply vessels and consequently improve the potential of metastasis in the targeted tumors. [ 18 ] Hence, optimizing the particle size would help fulfill this study's therapeutic goals. Different investigations prove that the nanoparticles prepared by nanoprecipitation have a smaller size than the single emulsion solvent evaporation method.…”

Section: Resultsmentioning

confidence: 99%

Targeted Delivery of Anticancer Drug Loaded Charged PLGA Polymeric Nanoparticles Using Electrostatic Field

Miraghaie,

Zandi,

Davari

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

Pure positive electrostatic charges (PPECs) show suppressive effect on the proliferation and metabolism of invasive cancer cells without affecting normal tissues. PPECs are used for the delivery of drug‐loaded polymeric nanoparticles (DLNs) capped with negatively charged poly(lactide‐co‐glycolide) (PLGA) and Poly(vinyl‐alcohol) PVA into the tumor site of mouse models. The charged patch is installed on top of the skin in the mouse models' tumor region, and the controlled selective release of the drug is assayed by biochemical, radiological, and histological experiments on both tumorized models and normal rats' livers. It is found that DLNs synthesized by PLGA show great attraction to PPECs due to their stable negative charges, which would not degrade immediately in blood. The burst and drug release after less than 48h of this synthesized DLNs are 10% and 50%, respectively. These compounds can deliver the loaded‐drug into the tumor site with the assistance of PPECs, and the targeted‐retarded release will take place. Hence, local therapy can be achieved with much lower drug concentration (conventional chemotherapy [2 mg kg−1] versus DLNs‐based chemotherapy [0.75 mg kg−1]) with negligible side effects in non‐targeted organs. PPECs have many potential clinical applications for advanced‐targeted chemotherapy with the lowest discernible side effects.

show abstract

Section: Resultsmentioning

confidence: 99%

Targeted Delivery of Anticancer Drug Loaded Charged PLGA Polymeric Nanoparticles Using Electrostatic Field

Miraghaie,

Zandi,

Davari

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…Ligand molecules may be attached to the liposomal surface or vesicles for actively target to the cancer cells. Ligands such as antibody or aptamer, proteins, peptides which are conjugated or tagged with the lipid vesicles covalently or non-covalently can easily recognize the neoplastic cells which are specific to the cancer cells or to the endothelial cells of the tumor vasculature (Figure 6 and Table 1) [33]. Nanomedicine for Targeted Drug Delivery in Cancer Chemotherapy DOI: http://dx.doi.org/10.5772/intechopen.114066…”

Section: Nanoliposome or Nanolipid Vesiclesmentioning

confidence: 99%

Nanomedicine for Targeted Drug Delivery in Cancer Chemotherapy

Shekhar Dey,

Kumari Dasgupta,

Deb Roy

2024

Pharmaceutical Science

View full text Add to dashboard Cite

Cancer is the uncontrolled proliferation of cells which subsequent spread of other organs of the human body (metastasis). The major therapeutic approaches of cancer chemotherapy are to deliver the correct amount of drug molecule in the desired site (malignant cells) for longer duration of action. Nanomedicine basically by passive as well as active targeting has been implemented for recognition, diagnosis and treatment for cancer and widely accepted in the modern field of oncology. Nanomedicine such as nanoliposomes and polymer based nanoparticles combine with genetic materials administered to the target cells for cancer chemotherapy. The advancement of nanomedicine will improve the therapeutic index of anticancer drug via modulation of pharmacokinetics parameters and tissue distribution to targeted sites. Ligand molecule can be tagged with this nanodevices for recognize the malignant cells via active targeting purposes and drug can be release at the site of specific target area followed by pre-programmed or predictable manner. This novel strategy of drug delivery technology is also applicable for conventional chemotherapy as well as metastatic state of the cancer patients. Targeting of neoplastic cells by nanocarriers play a vital role in novel drug delivery by protecting healthy normal cells from cytotoxicity as well as helpful for preventing the angiogenesis (neovascularization).

show abstract

“…Following the approval of the first nanomedicine Doxil ® by the Food and Drug Administration (FDA) for the treatment of various cancers, including metastatic breast cancer, numerous nanobased therapies for cancer treatment have emerged globally. These drug delivery systems (DDSs) can be broadly categorized into liposomal formulations (such as Doxil TM , Caelyx TM , Myocet TM , DaunoXome TM , Mepact TM , and Lipusu TM ), protein-drug conjugates (e.g., Abraxane TM and Pazenir TM ), and polymeric micelles (e.g., Genexol-PM) [152][153][154][155][156][157].…”

Section: Multifunctional Polymeric Nanoparticlesmentioning

confidence: 99%

“…Compared to conventional formulations, nanomedicine faces greater challenges in designing drug delivery systems, establishing evaluation profiles, scaling up manufacturing techniques, and overcoming regulatory barriers. Although the number and formulation of approved nanodrug delivery systems for cancer treatment are still limited, the development of versatile nanomedicines for clinical use now extends beyond cytotoxic drugs to include therapeutic agents such as siRNA, miRNA, and kinase inhibitors [152,154]. Table 1 summarizes the key features of nanoparticles that are under laboratory and clinical investigations for metastatic BC treatment.…”

Section: Multifunctional Polymeric Nanoparticlesmentioning

confidence: 99%

Metastatic Breast Cancer: Review of Emerging Nanotherapeutics

Dissanayake

Towner

Ahmed

2023

Cancers

View full text Add to dashboard Cite

Metastases of breast cancer (BC) are often referred to as stage IV breast cancer due to their severity and high rate of mortality. The median survival time of patients with metastatic BC is reduced to 3 years. Currently, the treatment regimens for metastatic BC are similar to the primary cancer therapeutics and are limited to conventional chemotherapy, immunotherapy, radiotherapy, and surgery. However, metastatic BC shows organ-specific complex tumor cell heterogeneity, plasticity, and a distinct tumor microenvironment, leading to therapeutic failure. This issue can be successfully addressed by combining current cancer therapies with nanotechnology. The applications of nanotherapeutics for both primary and metastatic BC treatments are developing rapidly, and new ideas and technologies are being discovered. Several recent reviews covered the advancement of nanotherapeutics for primary BC, while also discussing certain aspects of treatments for metastatic BC. This review provides comprehensive details on the recent advancement and future prospects of nanotherapeutics designed for metastatic BC treatment, in the context of the pathological state of the disease. Furthermore, possible combinations of current treatment with nanotechnology are discussed, and their potential for future transitions in clinical settings is explored.

show abstract

Nano drug delivery systems improve metastatic breast cancer therapy

Cited by 9 publications

References 138 publications

Targeted Delivery of Anticancer Drug Loaded Charged PLGA Polymeric Nanoparticles Using Electrostatic Field

Targeted Delivery of Anticancer Drug Loaded Charged PLGA Polymeric Nanoparticles Using Electrostatic Field

Nanomedicine for Targeted Drug Delivery in Cancer Chemotherapy

Metastatic Breast Cancer: Review of Emerging Nanotherapeutics

Contact Info

Product

Resources

About